In this report, the authors illustrated that ICB administration with either anti-CTLA-4, anti-PD-1, or anti-PD-L1 improved the glycolytic capacity and Interferon-gamma (IFNγ) production of CD8+ tumor-infiltrating T cells (8). This evidence concerns the gene IFNG and neoplasm.